For research use only. Not for therapeutic Use.
Fidaxomicin（Cat No.:A000989） is a narrow-spectrum antibiotic specifically used to treat Clostridioides difficile-associated diarrhea (CDAD). It works by inhibiting bacterial RNA polymerase, thereby preventing bacterial replication. Fidaxomicin is noted for its minimal systemic absorption and high fecal concentrations, making it effective in targeting C. difficile within the gastrointestinal tract while preserving normal gut flora. This reduces the risk of recurrence and promotes better patient outcomes. As an oral medication, Fidaxomicin offers a convenient and potent treatment option for CDAD, especially in patients who have failed to respond to other therapies.
| Catalog Number | A000989 |
| CAS Number | 873857-62-6 |
| Synonyms | OPT-80, PAR-101 |
| Molecular Formula | C52H74Cl2O18 |
| Purity | ≥95% |
| Target | RNA polymerase |
| Storage | -20°C |
| IUPAC Name | [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate |
| InChI | InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1 |
| InChIKey | ZVGNESXIJDCBKN-UUEYKCAUSA-N |
| SMILES | CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C |
